PDCD1 and neoplasm: Monoclonal antibodies STM418 (108), camrelizumab (17), mAb059c (109) and penpulimab (110) specifically target glycosylated PD-1 and have a high binding affinity for PD-1, effectively inhibiting PD-L1/PD-1 binding and enhancing anti-tumor immunity.